Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Core Insights - Corvus Pharmaceuticals reported positive data from cohort 4 of the Phase 1 trial for soquelitinib in patients with moderate-to-severe atopic dermatitis, leading to a significant increase in stock price and trading volume [1][9] Efficacy and Safety Results - Cohort 4 demonstrated favorable safety and efficacy results, with a deeper response over an 8-week treatment period compared to a 4-week period, and clinical activity observed in patients with prior systemic therapies [2] - The mean baseline EASI score was 25.7 for soquelitinib patients and 21.9 for placebo patients, indicating a higher severity of eczema in the treatment group [2] - Across all four cohorts (n=72), 35% of patients had prior systemic therapies, with 50% in cohort 4, and significant responses were noted in EASI 75 and IGA 0 or 1 endpoints [3] Treatment Outcomes - At day 56, the mean percent reduction in EASI for cohort 4 patients receiving soquelitinib was 72%, compared to 40% for placebo [3] - Continuous improvement in response was observed from day 28 to day 56, with no disease flares in the soquelitinib group compared to two in the placebo group [4] Biomarker Data - A reduction in serum IL-4 cytokine was noted in cohorts 3 and 4, with cohort 4 showing the largest reductions, indicating a dose-dependent response [5] - Serum IL-5 reduction occurred as early as day 8, with lower levels of IL-17 and TARC also observed [6] Safety Profile - As of January 15, no new safety signals were reported, with adverse events occurring in 41.7% of soquelitinib patients and 50% of placebo patients, all classified as Grade 1-2 [6] Future Trials - Corvus plans to initiate a Phase 2 clinical trial for soquelitinib in the first quarter of 2026, targeting approximately 200 patients who have failed prior therapies [7] - The trial will consist of four cohorts of 50 patients each, testing various dosages of soquelitinib alongside a placebo group [8]